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Introduction: Tumor lymphocyte infiltration is associated with clinical response to chemotherapy in estrogen
receptor (ER) negative breast cancer. To identify variants in immunosuppressive pathway genes associated with
prognosis after adjuvant chemotherapy for ER-negative patients, we studied stage I-III invasive breast cancer
patients of European ancestry, including 9,334 ER-positive (3,151 treated with chemotherapy) and 2,334 ER-negative
patients (1,499 treated with chemotherapy).
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Methods: We pooled data from sixteen studies from the Breast Cancer Association Consortium (BCAC), and
employed two independent studies for replications. Overall 3,610 single nucleotide polymorphisms (SNPs) in 133
genes were genotyped as part of the Collaborative Oncological Gene-environment Study, in which phenotype and
clinical data were collected and harmonized. Multivariable Cox proportional hazard regression was used to assess
genetic associations with overall survival (OS) and breast cancer-specific survival (BCSS). Heterogeneity according to
chemotherapy or ER status was evaluated with the log-likelihood ratio test.
Results: Three independent SNPs in TGFBR2 and IL12B were associated with OS (P <10−3) solely in ER-negative
patients after chemotherapy (267 events). Poorer OS associated with TGFBR2 rs1367610 (G > C) (per allele hazard
ratio (HR) 1.54 (95% confidence interval (CI) 1.22 to 1.95), P = 3.08 × 10−4) was not found in ER-negative
patients without chemotherapy or ER-positive patients with chemotherapy (P for interaction <10−3). Two SNPs in
IL12B (r2 = 0.20) showed different associations with ER-negative disease after chemotherapy: rs2546892 (G > A)
with poorer OS (HR 1.50 (95% CI 1.21 to 1.86), P = 1.81 × 10−4), and rs2853694 (A > C) with improved OS (HR 0.73
(95% CI 0.61 to 0.87), P = 3.67 × 10−4). Similar associations were observed with BCSS. Association with TGFBR2
rs1367610 but not IL12B variants replicated using BCAC Asian samples and the independent Prospective Study of
Outcomes in Sporadic versus Hereditary Breast Cancer Study and yielded a combined HR of 1.57 ((95% CI 1.28 to
1.94), P = 2.05 × 10−5) without study heterogeneity.
Conclusions: TGFBR2 variants may have prognostic and predictive value in ER-negative breast cancer patients treated
with adjuvant chemotherapy. Our findings provide further insights into the development of immunotherapeutic targets
for ER-negative breast cancer.Introduction
Breast cancer is still the leading cause of cancer-related
death in women despite improving survival rates of can-
cer patients due to earlier detection and expanded treat-
ment options [1], representing nearly 15% of cancer
deaths in women [2]. Although at least half of newly di-
agnosed patients present with early-stage breast cancer,
about 20% of these women will experience recurrence at
a distant site within 10 years of diagnosis despite chemo-
therapy and hormonal therapy options [3]. Therefore,
limitations of current therapeutic modalities, in particu-
lar for estrogen receptor negative (ER-negative) tumors
and ER-negative/progesterone receptor (PR-negative)
with low expression of human epidermal growth factor
receptor 2 (HER2) (triple-negative (TN)) tumors, have
led to search for new prognostic tools and therapy
targets.
Tumor immunoevasion is recognized as an emerging
hallmark of cancer, in addition to the tumor-promoting
inflammation [4]. Inhibition of immune response may
result from an immunosuppressive state in the tumor
microenvironment [5]. Two main types of immune
cells involved in the immunosuppression of cancer
are the regulatory T cells (Treg cells) and the mye-
loid derived suppressor cells (MDSCs). Treg cells refer
to a subset of T lymphocytes normally expressing
CD4 + CD25 + FOXP3+, which play an important role
in maintenance of self-tolerance and regulation of
immune response [6,7]. MDSCs are a heterogeneous
population of immature myeloid cells with expression of
CD11b + GR1+ including precursors of macrophages,granulocytes and dendritic cells, which are also involved
in tumor immunosuppression [8,9]. Tumor infiltration
by immune cells, including Treg cells and MDSCs, has
been implicated in cancer patient prognosis after chemo-
therapy [10-13]. ER-negative tumors typically show
higher levels of tumor-infiltrating lymphocytes than ER-
positive tumors [14,15]. Indeed, tumor lymphocyte infil-
tration, including Treg cells has been associated with
clinical response to chemotherapy and with prognosis in
ER-negative breast cancer [12,13,15], possibly due to the
sensitivity of infiltrating lymphocytes to chemotherapeu-
tic agents [16-18].
Therefore, we hypothesized that inherited common
variation in genes of the immunosuppressive pathway,
including Treg cells and MDSCs, could modulate re-
sponse to adjuvant chemotherapy, particularly among
ER-negative breast cancer patients. We evaluated genetic
associations of single nucleotide polymorphisms (SNPs)
located in or near (within 50 kb upstream and down-
stream) 133 candidate genes of the immunosuppressive
pathway with overall survival (OS) and breast cancer-
specific survival (BCSS) in breast cancer patients of
European ancestry from 16 Breast Cancer Association
Consortium (BCAC) studies [19] and performed replica-
tions for the variants with the strongest associations
using two independent patient samples.
Methods
Study sample
We selected women of European ancestry diagnosed
with histologically verified primary invasive but not
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stricted to women with available age information, be-
cause age is an important risk factor for breast cancer
(flow chart of patient selection in Additional file 1:
Figure S1). The cause of death for an individual patient
was recorded by hospital, cancer registry or health of-
fices in the respective studies. The majority of the stud-
ies were all carried out in developed countries where
deaths were accurately and mandatorily reported and
causes of death had to be reported by the physicians,
thus, the vast majority of deaths were reliably captured.
Follow up was censored at 10 years from study entry.
Studies with fewer than 10 events for all-cause mortality
within this period were excluded as well as women with
missing information on ER status, adjuvant chemother-
apy, vital status and cause of death. Excluded patients
had a similar mean age as compared to patients included
in the study (55.7 versus 56.8 years), had more family
history of breast cancer (30.53% versus 23.01%), had a
lower frequency in receiving adjuvant chemotherapy
(30.56% versus 39.85%), and had similar distribution in
tumor stage, grade, size, and ER/PR/HER2 status. A total
of 11,668 patients (9,334 with ER-positive disease, 2,334
with ER-negative disease) from 16 studies in BCAC were
included (Additional file 2: Table S1a). Of these patients,
4,650 patients (3,151 with ER-positive disease and 1,499
with ER-negative disease) had received adjuvant chemo-
therapy, 7,018 patients (6,183 with ER-positive disease
and 835 with ER-negative disease) did not receive
chemotherapy.
For the replication analyses in ER-negative patients
who had received adjuvant chemotherapy, we used four
Asian studies in BCAC as one sample set and the
Prospective Study of Outcomes in Sporadic versus
Hereditary breast cancer (POSH) study (consisting of
early-onset patients of European ancestry) as a second
sample set [20,21]. As for the discovery, we included
only ER-negative patients treated with adjuvant chemo-
therapy and restricted follow-up to 10 years after diag-
nosis. Thus, 372 breast cancer patients (42 events) from
the BCAC Asian studies and 127 early-onset breast can-
cer patients (62 events) in the POSH study were in-
cluded (Additional file 2: Table S1b). All studies were
approved by the relevant ethics committees and all par-
ticipants had signed an informed consent (Additional
file 2: Table S1a and S1b).
SNP selection and genotyping
Genes related to Treg cell and MDSC pathways were
identified through an extensive and comprehensive lit-
erature review in PubMed [22-34], using the search
terms immunosuppression/immunosuppressive, regula-
tory T cells/Treg cells/FOXP3+ T cells, myeloid derived
suppressor cells/MDSCs, immunosurveillance, and tumorescape, as only the broader immune pathways were access-
ible in the KEGG [35] and GO [36] databases. The final
candidate gene list included 133 immunosuppression-
related genes (Additional file 2: Table S2). SNPs with minor
allele frequency (MAF) >0.05 within 50 kb upstream and
downstream of each gene were identified using HapMap
CEU genotype data and dbSNP 126 as references [37].
For the BCAC studies, study samples were genotyped
for 211,155 SNPs using a custom Illumina iSelect array
(iCOGS) designed for the Collaborative Oncological
Gene-Environment Study (COGS) [19]. Of the 211,155
SNPs, 4,246 SNPs were located in the candidate genes
within a window of ±50 kb. A series of centralized qual-
ity controls after genotyping led to exclusion of 243
SNPs. The exclusion criteria included a called rate <95%
in all samples genotyped with iCOGS; being mono-
morphic; deviation from Hardy-Weinberg equilibrium
(HWE) with a P-value <10−7, and concordance in dupli-
cate samples <98%. After restricting the study sample to
the subjects eligible (n = 11,668), we additionally ex-
cluded 393 SNPs with MAF <0.05 and deviation from
HWE (P-value <10−7). A total of 3,610 SNPs passed all
quality controls and were analyzed.
We used imputed genotype data of the POSH study.
Imputation of POSH genome-wide association study
(GWAS) data (genotyped using the Illumina 660-Quad
SNP array, San Diego, CA, USA) was performed utiliz-
ing MACH 1.0 [38] based on the CEU population from
HapMap phase 2 [37] and a posterior probability of 0.9.
Imputation data were excluded based on MAF <0.01
and HWE with P-value <10−4. More details of POSH
data are described elsewhere [39].
Statistical methods
Cox proportional hazard regression analysis with right
truncation at 10 years after diagnosis was applied to
model patient survival. Each single SNP was assessed as
an ordinal variable (coded as 0, 1 and 2 respectively,
according to number of minor allele). Analyses were
adjusted for age at diagnosis and nine principal compo-
nents to account for population substructure and strati-
fied by study. To account for possible confounding due
to differences in patient characteristics, we included
tumor size, tumor grade and node status as further co-
variates. Delayed entry (left truncation) was used to re-
duce potential survival bias due to eligible patients who
died before recruitment into the study or before the
blood draw. Follow-up time was thus calculated from
the date of interview or blood draw until event or cen-
soring (date of last follow up). To determine the number
of independent SNPs for adjustment of multiple testing,
we applied the option, –indep-pairwise, in PLINK [40].
SNPs were pruned by linkage disequilibrium (LD) of
r2 < 0.2 for a window size of 50 SNPs and step size
Lei et al. Breast Cancer Research  (2015) 17:18 Page 4 of 13of 10, yielding 699 independent SNPs. The significance
threshold using Bonferroni correction corresponding to an
alpha of 5% had a P-value <7.15 × 10−5.
In the primary analysis, we modeled OS in a multivari-
ate Cox proportional hazard regression framework for
ER-negative breast cancer patients separately for those
who received adjuvant chemotherapy and those who did
not receive adjuvant chemotherapy. To investigate
whether SNP associations were restricted to ER-negative
breast cancer, we assessed heterogeneity of associations
between these two subgroups by using interaction terms
between chemotherapy and SNPs, which were evaluated
using likelihood ratio tests, comparing models with and
without the interaction term. We also assessed whether
selected SNPs associated with OS in ER-negative breast
cancer patients who received adjuvant chemotherapy
were associated with OS in ER-positive breast cancer pa-
tients treated with chemotherapy. Possible heterogeneity
in the associations of SNPs with OS for patients who
received chemotherapy according to ER status was
assessed statistically by using interaction terms between
ER status and SNPs and evaluated using likelihood ratio
tests. In secondary analysis, we evaluated SNP associa-
tions with OS separately for ER-negative/PR-negative
and TN breast cancer patients who received or did not
receive adjuvant chemotherapy, respectively. Addition-
ally, we assessed the associations of the SNPs with breast
cancer-specific survival (BCSS) in ER-negative patients
who received adjuvant chemotherapy. All statistical tests
mentioned above were two-sided and conducted using
SAS 9.2 (Cary, NC, USA).
For genes with multiple associated SNPs, HaploView
was used to examine LD between SNPs. To identify po-
tentially independently associated SNPs, we ran models
including multiple associated SNPs within a gene. The
proportional hazard assumption for the associated SNPs
was assessed according to Grambsch and Therneau [41]
and no significant deviation was noted. Cluster plots for
the most significant SNPs were examined among BCAC
samples and all showed good discrimination of three
genotypes.
Meta-analyses were performed to summarize the re-
sults from the discovery and replication studies and to
determine study heterogeneity using the I2 index and
Q-statistics [42,43] and forest plots were generated
using R (version 2.15.2).
Results
A descriptive summary of characteristics of the study
population with available follow-up information is given
in Table 1. There were 9,334 ER-positive breast cancer
patients and 2,334 ER-negative breast cancer patients, of
whom 1,904 had ER-negative/PR-negative disease and
1,007 TN disease. Of patients who had received adjuvantchemotherapy, 3,151 had ER-positive disease (376 events),
1,499 ER-negative disease (267 events), 1,271 ER-negative/
PR-negative disease (221 events) and 692 TN disease
(111 events).
A quantile-quantile (QQ) plot for tests of associations
with OS for the 3,610 evaluated SNPs in ER-negative
breast cancer patients who received adjuvant chemother-
apy is shown in Figure 1. Three independent genetic var-
iants in the two genes, TGFBR2 and IL12B, showed
associations with OS (P <10−3) only in ER-negative
breast cancer patients who received adjuvant chemother-
apy. None of the associations was significant after Bonfer-
roni correction (P <7.15 × 10−5) (Table 2). In ER-negative
breast cancer patients who did not receive chemotherapy,
none of the SNPs were associated (P <10−3). The results
for all assessed 3,610 SNPs in ER-negative breast cancer
patients treated with adjuvant chemotherapy are summa-
rized in Additional file 2: Table S3.
In TGFBR2, the strongest association in ER-negative pa-
tients who received chemotherapy was seen for SNP
rs1367610 (G >C) (per allele hazard ratio (HR) 1.54 (95%
confidence interval (CI) 1.22, 1.95), P= 3.08 × 10−4). A re-
gional association plot for all SNPs in TGFBR2 is shown in
Figure 2. The Kaplan-Meier survival curve stratified by
genotype of SNP rs1367610 is shown in Figure 3. For the
univariate survival curves, the P-value of the log-rank test
was 2.0 × 10−4. There was no evidence of heterogeneity for
the association across eight studies with at least ten events in
ER-negative patients with chemotherapy (Additional file 1:
Figure S2). This SNP was not associated with OS in ER-
negative patients who did not receive chemotherapy (P-value
for interaction = 8.82 × 10−4) or with ER-positive patients
who received chemotherapy (P-value for interaction =
2.62 × 10−4). Variant alleles of nine further SNPs in TGFBR2
in strong LD with rs1367610 (r2 ≥ 0.97) were similarly asso-
ciated with poorer OS in ER-negative breast cancer
patients treated with chemotherapy (Additional file 2:
Table S3). After accounting for rs1367610, none of other
nine TGFBR2 variants showed association with OS.
Two independent SNPs in IL12B (r2 = 0.20) showed
associations with ER-negative disease after chemo-
therapy: rs2546892 (G > A) with poorer OS (HR 1.50
(95% CI 1.21, 1.86), P = 1.81 × 10−4), and rs2853694
(A > C) with improved OS (HR 0.73 (95% CI 0.61, 0.87),
P = 3.67 × 10−4). These SNPs were not associated with OS
in ER-negative patients who did not receive chemother-
apy (P-value for interaction: 2.53 × 10−2 for rs2546892,
1.98 × 10−2 for rs2853694), or in ER-positive patients
who received chemotherapy (P-value for interaction:
4.63 × 10−3 for rs2546892, 2.27 × 10−2 for rs2853694)
(Table 2). Three other SNPs in IL12B (rs2853697,
rs2569254 and rs3181225) in high LD with rs2546892
(r2 ≥ 0.81, Additional file 1: Figure S3a) were also associated
with OS (P <10−3) (Additional file 2: Table S3). After
Table 1 Characteristics of the BCAC European study participants
Characteristics ER-negative patients who
received chemotherapy
Percent ER-negative patients who did
not receive chemotherapy
Percent ER-positive patients who
received chemotherapy
Percent
Number of patients 1499 100.00 835 100.00 3151 100.00
Age at diagnosis (mean ± SD, years) 51.69 ± 10.85 59.46 ± 12.18 51.74 ± 9.88
Family history
No 974 64.98 457 54.73 2233 70.87
Yes 275 18.35 148 17.72 596 18.91
Missing 250 16.68 230 27.54 322 10.22
Tumor stage
1 356 23.75 401 48.02 606 19.23
2 804 53.64 259 31.02 1751 55.57
3 182 12.14 58 6.95 526 16.69
Missing 157 10.47 117 14.01 268 8.51
Histological grade
Well-differentiated 23 1.53 97 11.62 390 12.38
Moderately differentiated 293 19.55 310 37.13 1624 51.54
Poorly/undifferentiated 1183 78.92 428 51.26 1137 36.08
Tumor size
≤2 cm 664 44.30 528 63.23 1387 44.02
≥2 cm to ≤5 cm 744 49.63 271 32.46 1490 47.29
≥5 cm 91 6.07 36 4.31 274 8.70
Lymph node status
Negative 735 49.03 651 77.96 976 30.97
Positive 764 50.97 184 22.04 2175 69.03
PR status
PR-negative 1271 84.79 633 75.81 546 17.33
PR-negative HER2-negative 692 46.16 315 37.72 304 9.65
Results are presented as number of patients unless stated otherwise. BCAC, Breast Cancer Association Consortium; ER, estrogen receptor; PR, progesterone receptor;
SD, standard deviation; HER2, human epidermal growth factor receptor 2.
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three SNPs) was still associated with OS, suggesting
that there are two potential independently associated
variants in IL12B.
In the secondary analysis of ER-negative/PR-negative
patients who received chemotherapy, rs1488369 (A > G)
in a further gene, CCR9, was observed to be associated
with an improved OS (HR 0.72 (95% CI 0.59, 0.87),
P = 8.63 × 10−4), besides SNPs in TGFBR2 and IL12B
(Additional file 2: Table S4). An association was not
found for ER-negative PR-negative patients without
chemotherapy (P-value for interaction = 1.78 × 10−2).
This SNP was associated (HR 0.75 (95% CI 0.63, 0.90,
P = 1.70 × 10−3) in patients with ER-negative disease
(Additional file 2: Table S3).
In TN breast cancer patients treated with chemotherapy,
rs2285440 (A > C), rs1726599 (C > A) and rs6956139
(C > A) in moderate LD (r2 ≥ 0.38) located in HDAC9
showed associations with two-fold increased HRs (HR 1.92to 2.41, P <10−3) (Additional file 1: Figure S3b, Additional
file 2: Table S4). None of the three SNPs was associated
with OS in TN patients who did not receive chemotherapy.
SNP rs2285440 remained strongly associated (HR 2.09
(95% CI 1.06, 4.15) after adjusting for the other two SNPs.
This SNP showed a weaker association in patients
with ER-negative disease (HR 1.47 (95% CI 1.09, 1.98),
P = 1.26 × 10−2) (Additional file 2: Table S3).
Additionally, rs9863120 (A > G) located in EIF2A was
associated with a significantly improved OS in TN pa-
tients who received chemotherapy (per allele HR 0.53
(95% CI 0.38, 0.74), P = 1.87 × 10−4) but not those with-
out chemotherapy (P-value for interaction = 8.02 × 10−4)
(Additional file 2: Table S4). In patients with ER-
negative disease, this SNP showed a weaker association
(HR 0.78 (95% CI 0.65, 0.95), P = 1.43 × 10−2) (Additional
file 2: Table S3).
We also assessed the associations of the immunosup-
pressive pathway SNPs with BCSS among ER-negative
Figure 1 Quantile-quantile (QQ) plot of the observed P-values
for associations with overall survival in estrogen receptor
(ER)-negative patients who received chemotherapy. QQ plot
shows the observed -log10 P-values (y axis) versus the expected -log10
P-values (x axis) for association of 3,610 SNPs in the immunosuppression
pathway, with overall survival in ER-negative breast cancer patients who
received adjuvant chemotherapy. The black dots indicate that there is
inflation for observed associations.
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results were in line with the findings of the OS analysis.
The most strongly associated SNP rs1872987 in TGFBR2
with BCSS is in high LD with rs1367610 (r2 = 0.99, HR
1.69 (95% CI 1.31, 2.19), P = 6.26 × 10−5) and the same
SNPs in IL12B were found to be associated. Additionally,
an SNP, rs658230 (G >A) in PRKCQ, was associated with
an improved BCSS (per allele HR 0.70 (95% CI 0.57, 0.86),
P = 6.95 × 10−4) and an SNP rs9579165 (A >G) in FLT3
showed a poorer BCSS (per allele HR 1.87 (95% CI 1.30,
2.70), P = 7.73 × 10−4) (Additional file 2: Table S5).
We performed two independent replications for the
SNPs in TGFBR2 and IL12B specifically associated with
OS only in the ER-negative breast cancer patients
treated with adjuvant chemotherapy using the BCAC
Asian samples and the (European) POSH study. The as-
sociation of TGFBR2 rs1367610 with OS in ER-negative
patients after adjuvant chemotherapy was replicated in
both BCAC Asian samples (HR 2.18 (95% CI 0.85, 5.60),
P = 1.05 × 10−1) as well as in the POSH study (HR 1.59
(95% CI 0.94, 2.69), P = 8.39 × 10−2), and was significant
(HR 1.71 (95% CI 1.08, 2.72) in the replication samples
combined. IL12B rs2853694 and rs2546892 did not rep-
licate in the two studies. Meta-analysis of the discovery
and replication studies yielded for TGFBR2 rs1367610
an HR of 1.57 (95% CI 1.28, 1.94, P = 2.05 × 10−5) without
evidence of heterogeneity (I2 = 0%; P heterogeneity = 0.78)
(Table 3).Discussion
In this study, we found that common variants in
TGFBR2 have prognostic value for ER-negative breast
cancer patients who received adjuvant chemotherapy.
Our hypothesis was confirmed that this was specific
for ER-negative disease, as the TGFBR2 variants were
clearly not associated with OS in ER-positive breast
cancer patients who received chemotherapy. The
TGFBR2 variants also have predictive value, as the
association with OS in ER-negative breast cancer pa-
tients was significantly differential according to treat-
ment with chemotherapy.
TGFBR2 (3p22) encodes the transforming growth fac-
tor beta (TGF-β) receptor II, which is a transmembrane
serine/threonine protein kinase receptor in the TGF-β
signaling pathway [44]. As an important cytokine in
tumor microenvironment, TGF-β has been considered
to have a dual role in tumor suppression at early stages
but then later promoting tumor invasion and metastasis
[44,45]. Specifically, TGF-β functions as a stimulator in
the tumor microenvironment to promote Treg cell pro-
liferation and immune evasion [46]. An ER-negative
tumor is normally associated with a higher level of infil-
trating lymphocytes [14,15]. TGF-β receptor II plays a
key role in the TGF-β signaling pathway, as all three
TGF-β isoforms bind to this receptor [45]. Early genetic
loss of TGFBR2 may lead to rapid tumor growth [45].
TGFBR2 has been identified as a susceptibility locus for
breast cancer risk [19] and its expression in cancer-
associated fibroblasts was found to be a prognostic
marker for pre-menopausal breast cancer [47]. Since the
immune-modulatory activities of TGF-ß have implica-
tions for many diseases, many drugs targeting the TGF-
ß signaling have been developed. Based on our findings,
it is conceivable that TGFBR2 variants may have prog-
nostic and predictive value also for the outcome of TGF-
ß signal inhibition.
TGFBR2 rs1367610 was recently reported to be pos-
sibly associated with BCSS in ER-negative patients
treated with adjuvant chemotherapy using the COGS
samples, however, replication in independent studies was
not carried out [48]. The prior COGS study examined
associations with breast cancer survival for 7,020 SNPs
in 557 genes related to immune response and inflamma-
tion [48]. There were about 70 genes (1,694 SNPs) that
overlapped between the two studies. The discovery sam-
ple of our study is somewhat smaller due to restriction
to early breast cancer (stage I to III disease) and trunca-
tion of follow up to 10 years to minimize the influence
of comorbidity on survival. However, we confirmed the
prognostic value of TGFBR2 in the independent POSH
study as well as in the Asian samples without study
heterogeneity and also showed TGFBR2 variants to be
related to both OS and BCSS.
Table 2 TGFBR2 and IL12B SNPs associated with overall survival (P-value <0.001) in ER-negative patients with chemotherapy
Chr Gene SNP Minorallele MAF
ER-negative patients who received
adjuvant chemotherapy
ER-negative patients who did not receive adjuvant
chemotherapy
ER-positive patients who received adjuvant
chemotherapy
Cases,
number
Events,
number
HRa
(95% CI) P-value
Cases,
number
Events,
number
HRa
(95% CI) P-value P heterogeneity
b Cases,
number
Events,
number
HRa
(95% CI) P-value P heterogeneity
c
3 TGFBR2 rs1367610 C 0.14 1499 267
1.54
(1.22, 1.95)
3.08 × 10−4 834 155
0.78
(0.55, 1.13)
0.191 8.82 × 10−4 3151 376
0.88
(0.70, 1.10)
0.251 2.62 × 10−4
5 IL12B rs2546892 A 0.17 1499 267
1.50
(1.21, 1.86)
1.81 × 10−4 835 155
0.99
(0.74, 1.33)
0.968 0.025 3151 376
0.99
(0.82, 1.20)
0.940 4.63 × 10−3
5 IL12B rs2853694 C 0.51 1499 267
0.73
(0.61, 0.87)
3.67 × 10−4 835 155
1.06
(0.85, 1.33)
0.596 0.020 3151 376
0.95
(0.82, 1.10)
0.529 0.023
aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and nine principal components to account for population substructure and stratified by study. bP-value for test of heterogeneity between ER-negative
breast cancer patients who received adjuvant chemotherapy and ER-negative breast cancer patients who did not receive adjuvant chemotherapy. cP-value for test of heterogeneity between ER-negative breast cancer patients
who received adjuvant chemotherapy and ER-positive breast cancer patients who received adjuvant chemotherapy. TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; ER, estrogen
receptor; Chr, chromosome; MAF, minor allele frequency; HR, hazard ratio; IL12B, interleukin 12B; and CI, confidence interval.
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Figure 2 Regional association plot for single nucleotide polymorphisms (SNPs) in TGFBR2. The regional plot shows associations with
overall survival in ER-negative breast cancer patients who received adjuvant chemotherapy, for all SNPs in TGFBR2. The y-axis shows the -log10
P-value. The purple diamond indicates SNP rs1367610, with the most significant association in TGFBR2. Chr, chromosome.
Lei et al. Breast Cancer Research  (2015) 17:18 Page 8 of 13All the top SNPs (P-value <10−3) in TGFBR2 were in
the intron of this gene. According to the UCSC genome
browser, the best-hit rs1367610 is located in the tran-
scription factor binding site, and rs1019856, rs1841528
and rs6550007 are in both the DNase I hypersensitivity
clusters and transcription factor binding sites. InFigure 3 Kaplan-Meier survival curves of overall survival in
estrogen receptor (ER)-negative patients who had chemotherapy
for TGFBR2 rs1367610. The survival curves for TGFBR2 rs1367610
(G > C) stratified by genotype are shown for the Breast Cancer
Association Consortium European sample. The P-value of the
log-rank test was 2.0 × 10−4. The number of events and cases in
parenthesis for each genotype are GG (180/1139, blue line), GC
(80/338, green line) and CC (7/22, red line) respectively.addition, from the HaploReg online tool, we found
that rs6550007 (r2 = 0.98 with rs1367610) may change
the binding site of forkhead box P3 (Foxp3), which is
an important transcription factor and a typical surface
marker of Treg cells (Additional file 1: Figure S4). The
top TGFBR2 SNPs associated with breast cancer OS are
not included in the GeneVar gene expression variation
database [49]. They lay in a different LD block from that
of the reported breast cancer risk-associated SNPs that
led to the identification of TGFBR2 as a breast cancer
susceptibility locus [19]. Neither rs1367610 nor SNPs in
high LD was associated with breast cancer risk in the
BCAC studies. It would be worth looking for potential
regulatory SNPs further than 50 kb away, and further
functional analyses are necessary to identify the causal
variant.
Although IL12B was found to be associated with
OS and with BCSS, also reported as possibly associ-
ated in the previous publication [48], we were not
able to replicate this finding using the two studies,
which were smaller than the discovery sample. If a
real association was overestimated in the discovery
sample, a much larger study sample would be re-
quired for replication. IL12B (5q31.1-q33.1) encodes
IL12 p40, which acts as a subunit of the heterodi-
meric structure of cytokine IL12 and IL23, two im-
portant immune cytokines in cell-mediated immunity
[50,51]. IL12 and IL23 can separately promote naïve
T cells into T helper (Th)1 cells and Th17 cells
in vivo [51], and the balance between Th17 cells and
Treg cells is a key factor in maintaining a normal
immune response [52].
Table 3 Associations of TGFBR2 and IL12B SNPs with overall survival in discovery and replication samples
Breast cancer patients TGFBR2 rs1367610 (G > C) IL12B rs2546892 (G > A ) IL12B rs2853694 (A > C)
Cases,
number
Events,
number
HR (95% CI) P-value Cases,
number
Events,
number
HR (95% CI) P-value Cases,
number
Events,
number
HR (95% CI) P-value
Discovery
ER-negative and received
chemotherapya
1499 267 1.54 (1.22, 1.95) 3.08 × 10−4 1499 267 1.50 (1.21, 1.86) 1.81 × 10−4 1499 267 0.73 (0.61, 0.87) 3.67 × 10−4
I2c = 86.7%; P heterogeneityd = 5.00 × 10−4 I2c = 78.5%; P heterogeneityd = 9.50 × 10−3 I2c = 75.9%; P heterogeneityd = 0.016
Replication
ER-negative and received
chemotherapy
BCAC Asian studiesa 372 42 2.18 (0.85, 5.60) 0.105 372 42 0.62 (0.30, 1.26) 0.187 372 42 1.03 (0.63, 1.67) 0.919
POSH studyb 127 62 1.59 (0.94, 2.69) 0.084 127 62 1.09 (0.67, 1.78) 0.715 127 62 0.87 (0.62, 1.22) 0.408
Combined replication
ER-negative and received
chemotherapy
499 104 1.71 (1.08, 2.72) 0.022 499 104 0.91 (0.61, 1.36) 0.659 499 104 0.92 (0.69, 1.21) 0.535
I2c = 0%; p heterogeneityd = 0.567 I2c = 40.4%; P heterogeneityd = 0.20 I2c = 0%; P heterogeneityd = 0.577
Combined overall
ER-negative received adjuvant
chemotherapy
1998 371 1.57 (1.28, 1.94) 2.05 × 10−5 1998 371 1.11 (0.70, 1.76) 0.653 1998 371 0.78 (0.67, 0.90) 8.00 × 10−4
I2c = 0%; P heterogeneityd = 0.781 I2c = 68.3%; P heterogeneityd = 0.04 I2c = 6.4%; P heterogeneityd = 0.344
aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and principal components to account for population substructure and stratified by study. bHR adjusted for age of diagnosis, tumor size,
tumor grade, node status and metastasis status. cI2 index derived on the basis of effect estimate and variance in each study. dP-value for test of heterogeneity between studies using the DerSimonian-Laird test.
TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; HR, hazard ratio; ER, estrogen receptor; BCAC, Breast Cancer Association Consortium; IL12B, interleukin 12B; CI,
confidence interval; and POSH, Prospective Study of Outcomes in Sporadic versus Hereditary Breast Cancer.
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Lei et al. Breast Cancer Research  (2015) 17:18 Page 10 of 13Further genes, LZTFL1/CCR9, HDAC9 and EIF2A, as
well as PRKCQ and FLT3, were implicated to play a role
in OS and/or BCSS for ER-negative patients after
chemotherapy. These findings warrant follow up in large
patient samples, because more variants in immunosup-
pressive pathway genes are potentially associated with
prognosis of breast cancer.
Three GWAS studies to date have been carried out
to investigate inherited genetic variants associated
with overall or breast cancer-specific mortality of
breast cancer [39,53,54]. In part due to the moderate
study size involved, few associations have been iden-
tified and confirmed. On the other hand, a GWAS of
clinical outcome in breast cancer patients who re-
ceived adjuvant tamoxifen therapy identified a new
locus associated with recurrence-free survival [55].
Therefore, germ-line genetic variation associated with
breast cancer prognosis may be more easily detected
when considering specific treatment subgroups and/or
cancer subtypes.
The main strengths of this study include the uniform
genotyping procedures, stringent centralized quality
controls and large sample size, which provides us with
sufficient statistical power to detect associations be-
tween genetic variants with moderate effects and
breast cancer prognosis. The availability of centrally
collated and harmonized information on molecular
subtype, clinical treatment, and follow up in BCAC
allowed us to assess potential differential SNP associa-
tions according to chemotherapy and also according to
ER status. We used the iCOGS array with 3,610 SNPs
to comprehensively assess these pathways. However,
tagging SNP coverage varied across different candidate
genes and could not capture variation entirely across
all of the immunosuppressive pathway-related loci.
Only genotyped data but not imputed data were used.
As we focused on single SNP assessment and did not
perform multi-marker analyses, we might have not
captured all truly associated loci. Two independent
study samples were employed to replicate the most
promising findings. The replication in the Asian popu-
lation, a different ethnic group, also suggests that the
observed association with TGFBR2 variants is likely to
be real. However, further genetic and functional stud-
ies are still required to identify the causal variants and
the mechanisms underlying the associations observed
in this study.
Conclusions
Our findings indicate that elucidating genetic variants,
which influence inhibition of tumor immunity, may pro-
vide prognostic and predictive markers of chemotherapy
for ER-negative breast cancer and could lead to further
therapy targets.Additional files
Additional file 1: Figure S1. Flow chart of patient selection. Figure S2
Forest plot of eight studies with at least ten events for TGFBR2
rs1367610. Figure S3a Linkage disequilibrium of five top single
nucleotide polymorphisms (SNPs) in IL12B associated with estrogen
receptor (ER)-negative patients with chemotherapy. Figure S3b linkage
disequilibrium of seven top SNPs in HDAC9 associated with triple-negative
patients with chemotherapy. Figure S4 UCSC browser graphic for TGFBR2
rs1367610.
Additional file 2: Table S1. Description of studies included: (S1a)
Sixteen Breast Cancer Association Consortium (BCAC) European studies in
the discovery analysis; (S1b) Four BCAC Asian studies and Prospective
Study of Outcomes in Sporadic versus Hereditary Breast Cancer (POSH)
study in the replication analysis. Table S2 List of 133 candidate genes
related to the immunosuppressive pathway by chromosomal position.
Table S3 Associations of 3610 single nucleotide polymorphisms (SNPs) in
the immunosuppressive pathway with overall survival in estrogen
receptor (ER)-negative patients with chemotherapy. Table S4 Top SNPs
associated with overall survival of ER-negative/progesterone receptor
(PR)-negative and triple-negative patients who received chemotherapy.
Table S5 Top SNPs associated with breast cancer-specific survival of ER-
negative patients who received chemotherapy.
Abbreviations
BCAC: Breast Cancer Association Consortium; BCSS: breast cancer-specific
survival; CCR9: chemokine (C-C motif) receptor 9; CI: confidence interval;
COGS: Collaborative Oncological Gene-Environment Study; EIF2A: eukaryotic
translation initiation factor 2 alpha; ER: estrogen receptor; FLT3: fms-related
tyrosine kinase 3; Foxp3: forkhead box P3; GWAS: genome-wide
association studies; HDAC9: histone deacetylase 9; HER2: human
epidermal growth factor receptor 2; HR: hazard ratio; HWE: Hardy-Weinberg
equilibrium; IL12B: interleukin 12B; LD: linkage disequilibrium; LZTFL1: leucine
zipper transcription factor-like 1; MAF: minor allele frequency; MDSCs: myeloid
derived suppressor cells; OS: overall survival; POSH: Prospective Study of
Outcomes in Sporadic versus Hereditary Breast Cancer Study;
PR: progesterone receptor; PRKCQ: protein kinase C, theta; QQ: quantile-
quantile; SD: standard deviation; SNP: single nucleotide polymorphism;
TGFBR2: transforming growth factor, beta receptor II; TGF-β: transforming
growth factor beta; Th: T helper; TN: triple negative; Treg cells: regulatory T cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
J Lei, AR, and SB participated in the design of the study, performed the
statistical analysis, and drafted the manuscript. KBM, ELG, DFE, MKS, and JCC
conceived the study, and participated in its design and coordination and
helped to draft the manuscript. SR, PDPP, PS, PAF, ILA, VNK, FJC, UH, MJH,
HN, UE, MKB, JD, QW, AL, AM, DL, MGC, PH, GCT, MS, RL, LH, ABE, MWB, JAK,
GG, ST, GIGA, ALBD, SN, JEO, EH, CV, DT, HUU, TR, AJ, CHMD, MMATL, TAM,
KA, CB, SM, VMK, JMH, VK, SH, HW, AS, JF, SJC, J Lissowska, J Li, KH, KAP,
kConFab Investigators, SL, SC, SAJB, DK, JYC, SKP, KYY, CNH, PEW, MFH, CYS,
SHT, NAMT, CHY, GFH, KM, H Ito, H Iwata, KT, AMD, JB, KC, LES, TM, WJT, and
DE participated in the study design and helped to draft the manuscript. All
authors read and approved the final manuscript.
Authors’ information
kConFab Investigators: Research Department, Peter MacCallum Cancer
Center, East Melbourne, Victoria 3002, Australia. Georgia.
Trench@qimrberghofer.edu.au.
Acknowledgements
We thank all the individuals who took part in these studies and all the
researchers, clinicians, technicians, and administrative staff who have enabled
this work to be carried out. This study would not have been possible without
the contributions of the following: Kyriaki Michailidou, (BCAC), Andrew Berchuck
(OCAC), Rosalind A Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch
(PRACTICAL), Antonis Antoniou, Lesley McGuffog and Ken Offit (CIMBA),
Andrew Lee, Ed Dicks, Graig Luccarini and the staff of the Centre for
Lei et al. Breast Cancer Research  (2015) 17:18 Page 11 of 13Genetic Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of
the CNIO genotyping unit, Jacques Simard and Daniel C Tessier, Francois Bacot,
Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of
the McGill University and Génome Québec Innovation Centre, Stig E.
Bojesen, Sune F Nielsen, Borge G Nordestgaard, and the staff of the
Copenhagen DNA laboratory, and Julie M Cunningham, Sharon A Windebank,
Christopher A Hilker, Jeffret Meyer and the staff of Mayo Clinic Genotyping Core
Facility. ABCS would like to thank Annegien Broeks, Emiel Rutgers, Laura van ’t
Veer, Richard van Hien, Frans Hogervorst, Senno Verhoef. HEBCS would like to
thank Kirsimari Aaltonen, Karl von Smitten, Sofia Khan, Tuomas Heikkinen and
Irja Erkkilä. KBCP thanks Eija Myöhänen and Helena Kemiläinen. LMBC thanks
Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen
Corthouts. MARIE thanks Judith Heinz, Nadia Obi, Alina Vrieling, Muhabbet
Celik, Til Olchers and Stefan Nickels. NBCS would like to thank the following
clinical collaborators: Professor Per Eystein Lønning, MD (Section of Oncology,
Institute of Medicine, University of Bergen and Department of Oncology,
Haukeland University Hospital, Bergen, Norway), Professor Emeritus Sophie D
Fosså, MD (National Resource Centre for Long-term Studies after Cancer,
Rikshospitalet-Radiumhospitalet Cancer Clinic Montebello, Oslo, Norway),
Head physician Tone Ikdahl, MD (Department of Oncology, Oslo University
Hospital, Oslo, Norway), Dr Lars Ottestad, MD (Department of Genetics and
Department of Oncology, Oslo University Hospital Radiumhospitalet), Dr Marit
Muri Holmen, MD (Department of Radiology, Oslo University Hospital
Radiumhospitalet, Oslo, Norway), Dr Vilde Haakensen, MD (Department
of Genetics and Department of Oncology, Oslo University Hospital
Radiumhospitalet and Institute for Clinical Medicine, Faculty of Medicine,
University of Oslo, Oslo, Norway), Professor Bjørn Naume, MD (Division of
Cancer Medicine and Radiotherapy, Department of Oncology, Oslo University
Hospital Radiumhospitalet, Oslo, Norway), Professor Eiliv Lund (Department of
Community Medicine, Faculty of Health Sciences, University of Tromsø - The
Arctic University of Norway, Tromsø, Norway), Associate Professor Åslaug Helland,
MD (Department of Genetics, Institute for Cancer Research and Department of
Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway and Institute
of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway),
Professor Inger Torhild Gram, MD (Department of Community Medicine,
Faculty of Health Sciences, University of Tromsø and Norwegian Centre for
Integrated Care and Telemedicine, University Hospital of North Norway,
Tromsø, Norway), Professor Emeritus Rolf Kåresen, MD (Department of
Breast and Endocrine Surgery, Institute for Clinical Medicine, Ullevaal Hospital,
Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine,
University of Oslo, Oslo, Norway), Dr. Ellen Schlichting, MD (Department for
Breast and Endocrine Surgery, Oslo University Hospital Ullevaal, Oslo, Norway),
Professor Toril Sauer, MD (Department of Pathology at Akershus University
hospital, Lørenskog, Norway), Dr Olav Engebråten, MD (Institute for Clinical
Medicine, Faculty of Medicine, University of Oslo and Department of
Oncology, Oslo University Hospital, Oslo, Norway), Dr Margit Riis, MD
(Department of Surgery, Akershus University Hospital and Department
of Clinical Molecular Biology (EpiGen), Institute of Clinical Medicine, Akershus
University Hospital, University of Oslo, Lørenskog, Norway). OFBCR thanks
Teresa Selander and Nayana Weerasooriya. PBCS thanks Louise Brinton,
Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao
and Michael Stagner, RBCS would like to thank Petra Bos, Jannet Blom,
Ellen Crepin, Elisabeth Huijskens, Annette Heemskerk and the Erasmus MC
Family Cancer Clinic. SASBAC would like to thank the Swedish Medical
Research Counsel. SEARCH thanks Craig Luccarini, Caroline Baynes, Don
Conroy, Anne Stafford, Sue Irvine, Barbara Perkins, Val Rhenius. SKKDKFZS
thank all study participants, clinicians, family doctors, researchers and
technicians for their contributions and commitment to the study. kConFab/AOCS
wish to thank Heather Thorne, Eveline Niedermayr, Charmaine Smith, Sandra
Picken, all the kConFab research nurses and staff, the heads and staff of the
Family Cancer Clinics, and the kConFab Follow Up Study for their contributions
to this resource, and the many families who contribute to kConFab. MYBRCA
thanks Phuah Sze Yee, Peter Kang, Kang In Nee, Kavitta Sivanandan, Shivaani
Mariapun, Yoon Sook-Yee, Daphne Lee and Teh Yew Ching for DNA extraction
and patient recruitment. Funding for the iCOGS infrastructure came from: the
European Community’s Seventh Framework Programme under grant
agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer
Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014,
C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health
(CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065
and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence(W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the
CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure,
the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.
The BCAC is funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings
of the BCAC have been funded by the European Union COST program
(BM0606). The ABCS study was supported by the Dutch Cancer Society
(grants NKI 2007-3839; 2009 4363); BBMRI-NL, which is a Research Infrastructure
financed by the Dutch government (NWO 184.021.007); and the Dutch National
Genomics Initiative. The work of the BBCC study was partly funded by
ELAN-Fond of the University Hospital of Erlangen. The HEBCS study was
financially supported by the Helsinki University Central Hospital Research Fund,
Academy of Finland (266528), the Finnish Cancer Society, The Nordic Cancer
Union and the Sigrid Juselius Foundation. Financial support for KARBAC study
was provided through the regional agreement on medical training and clinical
research (ALF) between Stockholm County Council and Karolinska Institute, the
Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von
Kantzows foundation. The KBCP study was financially supported by the
special Government Funding (EVO) of Kuopio University Hospital grants,
Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the
strategic funding of the University of Eastern Finland. The LMBC study is
supported by the Stichting tegen Kanker (232–2008 and 196–2010). The
MARIE study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I,
106332, 108253, 108419), the Hamburg Cancer Society, the German Cancer
Research Center and the Federal Ministry of Education and Research (BMBF)
Germany (01KH0402). The MCBCS study was supported by the NIH grants
CA128978, CA116167, CA176785 and NIH Specialized Program of Research
Excellence (SPORE) in Breast Cancer (CA116201), and the Breast Cancer Research
Foundation and a generous gift from the David F and Margaret T Grohne Family
Foundation and the Ting Tsung and Wei Fong Chao Foundation. The NBCS
study was supported by grants from the Norwegian Research council, 155218/
V40, 175240/S10 to ALBD, FUGE-NFR 181600/V11 to VNK and a Swizz Bridge
Award to ALBD. The OFBCR study was supported by grant UM1 CA164920 from
the National Cancer Institute (USA). The PBCS study was funded by Intramural
Research Funds of the National Cancer Institute, Department of Health and
Human Services, USA. The RBCS study was funded by the Dutch Cancer Society
(DDHK 2004–3124, DDHK 2009–4318). The SASBAC study was supported by
funding from the Agency for Science, Technology and Research of Singapore
(A*STAR), the US National Institute of Health (NIH) and the Susan G Komen
Breast Cancer Foundation. The SEARCH study is funded by a program grant
from Cancer Research UK (C490/A10124)] and supported by the UK National
Institute for Health Research Biomedical Research Centre at the University of
Cambridge. The SKKDKFZS study is supported by the German Cancer Research
Center. The kConFab study is supported by a grant from the National Breast
Cancer Foundation, and previously by the National Health and Medical Research
Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New
South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation
of Western Australia. The kConFab follow-up study has received funding from
the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the
National Institute of Health (USA). KAP is a National Breast Cancer Foundation
Fellow (Australia). The HERPACC study was supported by a Grant-in-Aid for
Scientific Research on Priority Areas from the Ministry of Education, Science,
Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third
Term Comprehensive 10-Year Strategy for Cancer Control from Ministry
Health, Labour and Welfare of Japan, by Health and Labour Sciences Research
Grants for Research on Applying Health Technology from Ministry Health, Labour
and Welfare of Japan and by National Cancer Center Research and Development
Fund. The MYBRCA study is funded by research grants from the Malaysian
Ministry of Science, Technology and Innovation (MOSTI), Malaysian Ministry
of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives
Foundation (CARIF). Additional controls were recruited by the Singapore
Eye Research Institute, which was supported by a grant from the Biomedical
Research Council (BMRC08/1/35/19/550), Singapore and the National medical
Research Council, Singapore (NMRC/CG/SERI/2010). The SEBCS study was
supported by the BRL (Basic Research Laboratory) program through the
National Research Foundation of Korea funded by the Ministry of Education,
Science and Technology (2012-0000347). The TWBCS study is supported by
the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia
Sinica, Taiwan. The POSH study was supported by Funding Breast Cancer
Campaign (NOV210PR62) and Cancer Research UK (C1275/A9896). The
content of this manuscript does not necessarily reflect the views or
policies of the National Cancer Institute or any of the collaborating centers
Lei et al. Breast Cancer Research  (2015) 17:18 Page 12 of 13in the Breast Cancer Family Registry (BCFR), nor does mention of trade
names, commercial products, or organizations imply endorsement by the
USA Government or the BCFR. Douglas F Easton is a Principal Research Fellow
of Cancer Research UK. The funders had no roles in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Author details
1Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
Im Neuenheimer Feld 581, D-69120 Heidelberg, Germany. 2Department of
Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY
14263, USA. 3Faculty of Medicine, University of Southampton, University
Hospital Southampton, Southampton SO16 6YD, UK. 4Department of Health
Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. 5Centre for
Cancer Genetic Epidemiology, Department of Public Health and Primary
Care, University of Cambridge, Cambridge CB1 8RN, UK. 6Centre for Cancer
Genetic Epidemiology, Department of Oncology, University of Cambridge,
Worts Causeway, Cambridge CB1 8RN, UK. 7University Breast Center Franconia,
Department of Gynecology and Obstetrics, University Hospital Erlangen,
Friedrich-Alexander University Erlangen–Nuremberg, Universitätsstrasse 21-23,
91054 Erlangen, Germany. 8Division of Hematology and Oncology, Department
of Medicine, David Geffen School of Medicine, University of California at Los
Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095, USA. 9Ontario
Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of Mount
Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.
10Department of Molecular Genetics, University of Toronto, 1 King’s College
Circle, Toronto, Ontario M5S 1A8, Canada. 11Department of Genetics, Institute for
Cancer Research, Oslo University Hospital, Radiumhospitalet, Ullernchausseen 70,
N-0310 Oslo, Norway. 12K.G. Jebsen Center for Breast Cancer Research, Institute
for Clinical Medicine, Faculty of Medicine, University of Oslo, Kirkeveien 166, 0450
Oslo, Norway. 13Department of Clinical Molecular Biology (EpiGen), Medical
Division, Akershus University Hospital, Sykehusveien 25, 1478 Lørenskog, Norway.
14Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
55905, USA. 15Division of Molecular Genetics of Breast Cancer, German Cancer
Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg,
Germany. 16Department of Medical Oncology, Erasmus MC Cancer Institute,
Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands. 17Department of
Obstetrics and Gynecology, University of Helsinki and Helsinki University Central
Hospital, Haartmaninkatu 8, FI-00029 Helsinki, Finland. 18Department of Molecular
Medicine and Surgery, Karolinska Institutet, Stockholm SE-17177, Sweden.
19School of Medicine, Institute of Clinical Medicine, Oncology, University of
Eastern Finland, Yliopistonranta 1C, FI-70211 Kuopio, Finland. 20Biocenter Kuopio,
Cancer Center of Eastern Finland, University of Eastern Finland, FI-70211 Kuopio,
Finland. 21Cancer Center, Kuopio University Hospital, Puijonlaaksontie 2, 70210
Kuopio, Finland. 22Vesalius Research Center (VRC), VIB, Herestraat 49, 3000 Leuven,
Belgium. 23Laboratory for Translational Genetics, Department of Oncology,
University of Leuven, Herestraat 49, 3000 Leuven, Belgium. 24Division of Cancer
Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
25Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton
SM2 5NG, UK. 26Breakthrough Breast Cancer Research Centre, Division of Breast
Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK.
27Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box
281, 171 77 Stockholm, Sweden. 28QIMR Berghofer Medical Research Institute,
300 Herston Road, Brisbane, Queensland 4006, Australia. 29Institute of Human
Genetics, Friedrich Alexander University Erlangen-Nuremberg, Schlossplatz 4,
91054 Erlangen, Germany. 30Prosserman Centre for Health Research,
Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, 600 University
Avenue, Toronto, Ontario M5G 1X 5, Canada. 31Division of Epidemiology, Dalla
Lana School of Public Health, University of Toronto, 155 College Street, Toronto,
Ontario M5T 3M7, Canada. 32Lunenfeld-Tanenbaum Research Institute of Mount
Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada.
33Institute of Human Genetics, Pontificia Universidad Javeriana, Carrera 7, Bogotá
11001000, Colombia. 34Frauenklinik der Stadtklinik Baden-Baden, D-7570
Baden-Baden, Germany. 35Institute of Pathology, Städtisches Klinikum
Karlsruhe, Moltkestrasse 90, 76133 Karlsruhe, Germany. 36Department of
Pathology, Erasmus University Medical Center, 3075EA Rotterdam, The
Netherlands. 37Department of Surgical Oncology, Erasmus MC Cancer
Institute, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands.
38Department of Clinical Genetics, University of Helsinki and Helsinki
University Central Hospital, Haartmaninkatu 8, FI-00029 Helsinki, Finland.
39Department of Oncology, University of Helsinki and Helsinki University
Central Hospital, FI-00029 HUS Helsinki, Finland. 40Department ofOncology-Pathology, Karolinska Institutet, Stockholm SE-17177, Sweden.
41Jyväskylä Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, Finland.
42Multidisciplinary Breast Center, University Hospitals Leuven, Herestraat 49,
3000 Leuven, Belgium. 43Department of Cancer Epidemiology and
Prevention, Cancer Center and M Sklodowska-Curie Institute of Oncology,
02-781 Warsaw, Poland. 44Human Genetics, Genome Institute of Singapore,
60 Biopolis Street 02-01, Singapore 138672, Singapore. 45Saw Swee Hock
School of Public Health, National University of Singapore, MD3, 16 Medical
Drive, Singapore 117597, Singapore. 46Centre for Epidemiology and
Biostatistics, Melbourne School of Population and Global Health, University
of Melbourne, Level 1, 723 Swanston Street, Melbourne, Victoria 3010,
Australia. 47Sir Peter MacCallum Department of Oncology, University of
Melbourne, St Andrews Place East, East Melbourne, Victoria 3002, Australia.
48Division of Molecular Pathology, Netherlands Cancer Institute, Postbus
90203, 1006 BE Amsterdam, The Netherlands. 49Department of Preventive
Medicine, Seoul National University College of Medicine, 103 Daehak-ro,
Jongno-gu, Seoul 110-799, Korea. 50Department of Biomedical Sciences,
Seoul National University Graduate School, 1 Gwanak-ro, Gwanak-gu, Seoul
151-742, Korea. 51Seoul National University College of Medicine, 103
Daehak-ro, Jongno-gu, Seoul 110-799, Korea. 52Institute of Biomedical
Sciences, Academia Sinica, Academia Road Nankang, Taipei 115, Taiwan.
53Taiwan Biobank, Academia Sinica, Academia Road Nankang, Taipei 115,
Taiwan. 54Department of Surgery, Kaohsiung Medical University Chung-Ho
Memorial Hospital, No.100 , Tzyou 1st Road, Kaohsiung 807, Taiwan.
55College of Public Health, China Medical University, No. 91, Hsueh-Shih
Road, Taichung 40402, Taiwan. 56Cancer Research Initiatives Foundation,
Sime Darby Medical Centre, 1 Jalan SS 12/1A, Subang Jaya 47500, Selangor,
Malaysia. 57Breast Cancer Research Unit, Faculty of Medicine, University
Malaya Cancer Research Institute, University Malaya, Lembah Pantai, 59100
Kuala Lumpur, Malaysia. 58Department of Oncology, Faculty of Medicine,
University Malaya, Lembah Pantai, 59100 Kuala Lumpur, Malaysia.
59Department of Preventive Medicine, Faculty of Medical SciencesLembah
Pantai, Kyushu University, Fukuoka 812-8582, Japan. 60Division of
Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1
Kanokoden Chikusa-ku, Nagoya 464-8681, Aichi, Japan. 61Department of
Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku,
Nagoya 464-8681, Aichi, Japan. 62Epidemiology Center for Disease Control
and Prevention, Mie University Hospital, 1577 Kurimamachiya-cho, Tsu City,
Mie Prefecture 514-8507, Japan. 63Human Genotyping Unit-Centro Nacional
de Genotipado (CEGEN), Human Cancer Genetics Programme, Spanish
National Cancer Research Centre (CNIO), 28029 Madrid, Spain. 64Centro
de Investigación en Red de Enfermedades Raras (CIBERER), 46010 Valencia, Spain.
65Division of Psychosocial Research and Epidemiology, Netherlands Cancer
Institute, Postbus 90203, 1006 BE Amsterdam, The Netherlands.
Received: 2 September 2014 Accepted: 23 January 2015References
1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer
mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.
2. Breast Cancer - Estimated Incidence, Mortality and Prevalence Worldwide in
2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 23
June 2014.
3. Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. Lancet. 2005;365:1687–717.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating
immunity’s roles in cancer suppression and promotion. Science.
2011;331:1565–70.
6. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev
Immunol. 2008;8:523–32.
7. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells
in the human immune system. Nat Rev Immunol. 2010;10:490–500.
8. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking
inflammation and cancer. J Immunol. 2009;182:4499–506.
9. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of
myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.
Lei et al. Breast Cancer Research  (2015) 17:18 Page 13 of 1310. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-
associated lymphocytes as an independent predictor of response to
neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.
11. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes
predict response to neoadjuvant chemotherapy in breast cancer patients. J
Breast Cancer. 2013;16:32–9.
12. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic
and predictive value of tumor-infiltrating lymphocytes in a phase III
randomized adjuvant breast cancer trial in node-positive breast cancer
comparing the addition of docetaxel to doxorubicin with doxorubicin-based
chemotherapy: BIG 02–98. J Clin Oncol. 2013;31:860–7.
13. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.
Tumor-infiltrating lymphocytes predict response to anthracycline-based
chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res.
2011;13:R126.
14. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of
regulatory T cells enables the identification of high-risk breast cancer patients
and those at risk of late relapse. J Clin Oncol. 2006;24:5373–80.
15. Calabro A, Beissbarth T, Kuner R, Stojanov M, Benner A, Asslaber M, et al.
Effects of infiltrating lymphocytes and estrogen receptor on gene expression
and prognosis in breast cancer. Breast Cancer Res Treat. 2009;116:69–77.
16. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C,
et al. CD4 + CD25+ regulatory T cells suppress tumor immunity but are
sensitive to cyclophosphamide which allows immunotherapy of established
tumors to be curative. Eur J Immunol. 2004;34:336–44.
17. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer
chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for
antitumor immunity. Cancer Immunol Immunother. 2008;57:1579–87.
18. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H.
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced
immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–8.
19. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL,
et al. Large-scale genotyping identifies 41 new loci associated with breast
cancer risk. Nat Genet. 2013;45:353–61. 361e351-352.
20. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG, et al.
Prospective study of Outcomes in Sporadic versus Hereditary breast cancer
(POSH): study protocol. BMC Cancer. 2007;7:160.
21. Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, et al.
Prospective observational study of breast cancer treatment outcomes for
UK women aged 18–40 years at diagnosis: the POSH study. J Natl Cancer
Inst. 2013;105:978–88.
22. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the immune system. Nat Rev Immunol. 2009;9:162–74.
23. Mills KH. Regulatory T, cells: friend or foe in immunity to infection? Nat Rev
Immunol. 2004;4:841–55.
24. Zou W. Immunosuppressive networks in the tumour environment and their
therapeutic relevance. Nat Rev Cancer. 2005;5:263–74.
25. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance:
immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715–27.
26. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing
immune response: crosstalk between adaptive and innate immune cells
during breast cancer progression. Breast Cancer Res. 2007;9:212.
27. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor
and antitumor immunity. Curr Opin Genet Dev. 2008;18:11–8.
28. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al.
Macrophage polarization in tumour progression. Semin Cancer Biol.
2008;18:349–55.
29. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors
in anti-tumor immunity. Immunol Rev. 2009;229:126–44.
30. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes
and myeloid cells regulate pro- versus anti-tumor immunity. Cancer
Metastasis Rev. 2010;29:309–16.
31. Wilczynski JR, Duechler M. How do tumors actively escape from host
immunosurveillance? Arch Immunol Ther Exp (Warsz). 2010;58:435–48.
32. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor
escape from the immune system. Cancer Immunol Immunother.
2011;60:1161–71.
33. Krieg C, Boyman O. The role of chemokines in cancer immune surveillance
by the adaptive immune system. Semin Cancer Biol. 2009;19:76–83.
34. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity
and stability of regulatory T cells. Nat Rev Immunol. 2013;13:461–7.35. KEGG: Kyoto Encyclopedia of Genes and Genomes. http://www.
genome.jp/kegg/. Accessed 08 May 2014.
36. Gene Ontology Consortium. http://www.geneontology.org/. Accessed 09
May 2014.
37. International HapMap Project. www.hapmap.org. Accessed 23 June 2014.
38. University of Michigan: Center for Statistical Genetics. MACH 1.0. http://
www.sph.umich.edu/csg/abecasis/MACH/index.html. Accessed 30 April
2014.
39. Rafiq S, Tapper W, Collins A, Khan S, Politopoulos I, Gerty S, et al.
Identification of inherited genetic variations influencing prognosis in
early-onset breast cancer. Cancer Res. 2013;73:1883–91.
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet. 2007;81:559–75.
41. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics
based on weighted residuals. Biometrika. 1994;81:515–26.
42. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–88.
43. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis.
Stat Med. 2002;21:1539–58.
44. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression
and cancer progression. Nat Genet. 2001;29:117–29.
45. Akhurst RJ, Derynck R. TGF-beta signaling in cancer–a double-edged sword.
Trends Cell Biol. 2001;11:S44–51.
46. Ferretti G, Felici A, Cognetti F, Mandala M. Transforming growth factor-beta
signaling and regulatory T cells. J Clin Oncol. 2007;25:4695–6. author reply
4696–4697.
47. Busch S, Acar A, Magnusson Y, Gregersson P, Ryden L, Landberg G. TGF-
beta receptor type-2 expression in cancer-associated fibroblasts regulates
breast cancer cell growth and survival and is a prognostic marker in
pre-menopausal breast cancer. Oncogene. 2013;34:27–38.
48. Li J, Lindstrom LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, et al. 2q36.3 is
associated with prognosis for oestrogen receptor-negative breast cancer
patients treated with chemotherapy. Nat Commun. 2014;5:4051.
49. Wellcome Trust Sanger Institute. Genevar (GENe Expression VARiation).
http://www.sanger.ac.uk/resources/software/genevar/. Accessed 30 April
2014.
50. Kaarvatn MH, Vrbanec J, Kulic A, Knezevic J, Petricevic B, Balen S, et al.
Single nucleotide polymorphism in the interleukin 12B gene is associated
with risk for breast cancer development. Scand J Immunol. 2012;76:329–35.
51. Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory
bowel disease: clues to pathogenesis. Br Med Bull. 2008;87:17–30.
52. Yu X, Wang C, Luo J, Zhao X, Wang L, Li X. Combination with methotrexate
and cyclophosphamide attenuated maturation of dendritic cells: inducing
Treg skewing and Th17 suppression in vivo. Clin Dev Immunol.
2013;2013:238035.
53. Azzato EM, Pharoah PD, Harrington P, Easton DF, Greenberg D, Caporaso
NE, et al. A genome-wide association study of prognosis in breast cancer.
Cancer Epidemiol Biomarkers Prev. 2010;19:1140–3.
54. Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, et al. Novel genetic
markers of breast cancer survival identified by a genome-wide association
study. Cancer Res. 2012;72:1182–9.
55. Kiyotani K, Mushiroda T, Tsunoda T, Morizono T, Hosono N, Kubo M, et al. A
genome-wide association study identifies locus at 10q22 associated with
clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
in Japanese. Hum Mol Genet. 2012;21:1665–72.
